Stop TB Partnership


Upcoming Meetings

Previous Meetings

Read more about the TB Innovations Summit here.

May ’18 - Roundtable Discussion: Barriers in Country Adoption and Access to New, Quality Assured TB and AMR Products and Technologies (by invitation only)

In the lead-up to the United Nations High-Level Meeting on Tuberculosis ("UNHLM on TB"), which will take place on 26 September 2018, it will be critical to show that the TB community is able to unite to jointly develop sustainable solutions that will lead to the end of TB by 2030.

As such, the Stop TB Partnership and the World Economic Forum are organizing an event in May 2018 in Geneva, Switzerland in advance of the 71st World Health Assembly to discuss the key barriers to country adoption and access to new TB products and technologies in high burden countries (HBCs), and the role of multi-sectoral collaboration in bridging the gap.

The roundtable discussion will also bring together key decision-makers, partners, and stakeholders - such as Ministers of Health, civil society and communities, non-governmental organizations, private sector actors (both companies and service providers), donors, and private foundations - to better understand each other’s comparative advantages in facilitating country adoption, and collectively strategize on how the capabilities and expertise of the private sector can ensure that the people affected by TB and service providers have equitable and appropriate access to the TB products and technologies they need and want.

Oct. ’16 - 1st Stakeholder Consultation on a4i

The Stop TB Partnership organized the 1st Stakeholder Consultation on a4i, which was held on 28 October 2016 in Liverpool, United Kingdom in advance of the 27th Union World Conference on Lung Health. The meeting objectives were:

  • Commence and foster a regular dialogue on the barriers and opportunities countries, innovators, and key stakeholders in the TB space face to accelerate the introduction and scale-up of promising, new TB tools and
  • Introduce the a4i mechanism, which plans to directly address these barriers and optimize opportunities for prompt solutions.

The agenda and participant list can be found at

Oct. ’17 - 1st Focus Group Discussion on Digital Adherence Technologies

The Stop TB Partnership, in collaboration with the Arcady Group, organized the 1st Focus Group Discussion on Digital Adherence Technologies, which was held on 8 October 2017 in Guadalajara, Mexico in advance of the 48th Union World Conference on Lung Health. The meeting objectives were to:

  • Establish a shared understanding regarding adherence taxonomy, importance of proper adherence to existing TB treatments, including current practices and trends regarding treatment observation and monitoring;
  • Share information about the operation, potential benefit, evidence base, uptake trends, what is known and unknown, including clinical outcomes of 99DOTS, digital medication monitors (evriMED), video-observed therapy (VDOT), and Keheala;
  • Understand end-user’s expectations and needs regarding digital adherence technologies;
  • Share perspectives and learnings from current implementation of digital adherence technologies, including necessary conditions and enablers, resources required, and lessons learned; and
  • Identify what additional information countries would require, from a piloting and adopting perspective, to catalyze roll-out of digital adherence technologies at a national level.

The agenda, participants list, presentations, and summary can be found at

Oct. ’17 - 1st Innovators & Adopters Workshop on TB Diagnostics & Adjunct Technologies

The Stop TB Partnership, in collaboration with FIND, McGill International TB Centre, Unitaid, and World Health Organization, organized the 1st Innovators & Adopters Workshop in TB Diagnostics & Adjunct Technologies, which was held on 9 October 2018 in Guadalajara, Mexico in advance of the 48th Union World Conference on Lung Health. The meeting objectives were:

  • Strengthen collaboration and communication between innovators, country decision-makers and stakeholders, including civil society and communities, and key partners to accelerate the roll-out of new TBDx;
  • Present the critical stages, sequence of activities, and key partners to roll-out new TBDx;
  • Provide innovators with the opportunity to share their experiences along the pathway to roll-out their TBDx;
  • Share information regarding the WHO product validation process, how innovators and countries can leverage TB REACH, Unitaid, and the Global Fund to drive roll-out of TBDx, and why it is important to engage civil society and communities early along the pathway; and
  • Achieve better balance between supply and demand for TBDx.

The agenda, participant list, presentations, and summary can be found at